6:32 PM
Sep 11, 2008
 |  BC Extra  |  Company News

Genentech updates Rituxan label after PML case

Genentech (NYSE:DNA) issued a "Dear Healthcare Professional" letter and updated the label for Rituxan rituximab to reflect a case of progressive multifocal leukoencephalopathy (PML) leading to death in a patient with rheumatoid arthritis (RA) who...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >